{"name":"Epygenix","slug":"epygenix","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Clemizole HCl","genericName":"Clemizole HCl","slug":"clemizole-hcl","indication":"Allergic conditions and pruritus (investigational in Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"Clemizole HCl","genericName":"Clemizole HCl","slug":"clemizole-hcl","phase":"phase_3","mechanism":"Clemizole HCl is a histamine H1-receptor antagonist that blocks histamine-mediated immune and inflammatory responses.","indications":["Allergic conditions and pruritus (investigational in Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFBlUVRPdGpaNWNUZHhKTXJ4S3VQTjhmMjJGR2JEMkU4aWY1TnJiSjlfOUdEanZ0aUhEZkxZNk92YXQ4TGM4T19velEwUkl3VHNXS0tKYm9LYnZVYjRnU0pBRGhNaw?oc=5","date":"2025-10-20","type":"pipeline","source":"StreetInsider","summary":"Resistance to Epilepsy Treatments May Wane Over Time - StreetInsider","headline":"Resistance to Epilepsy Treatments May Wane Over Time","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxNelhGRWdNOUpyWkFNSHZzMml5MHFvYnpHMmVhN0RjRmZ6UW5WR0hMeTM2SG91enFaNUk0ODRmekxuQWxjMHo1eHRpRlR4ZXZLNFpIOEkzQTRMMnNDaWNiUXQtMFFON2VFSWRJUUp4MXUySklNUThyRXlVSlYyOEVyR1hENnBUT1gtQmtGTDE1clFDNmhYWWNGTG1VSVFWUXl1cnBSNW9Rdkdpa0FFU3RsWlZXVVVJc2VoOFZRZ1lPekVyTUtLZGNGM0cxMlZaQkstMFRzbkx5YVNHdzJmbm1qOEdKWFhQQ3dDNWFCZXJYS2JOUjhCM0Z2OVV0Z3NocUpVRTJSY3BKSzVoaVowOWpkZzROSXV3dkFVRm9EVVlxNmNPVmM?oc=5","date":"2025-04-08","type":"pipeline","source":"GlobeNewswire","summary":"Developmental and Epileptic Encephalopathies Market to - GlobeNewswire","headline":"Developmental and Epileptic Encephalopathies Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE4ycUhTcC15Wlo4R2hpaWp4eEt0bjJES1JFN2FCNjVZeUxhMlJHYzVMYlVRM0RYTVpWNHhVWFNNTXFjMkpQc3NGRFRwSEwtXzNoMEJpS0p5X21kOFZFa21TeXVxU1d1TnpxdFBfcHNKTGxlbVFDYmRITWc0RE51WEU?oc=5","date":"2025-01-22","type":"trial","source":"Yahoo Finance","summary":"5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance","headline":"5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNdFQ0aGt1TVk2ZF9zUkNrSFYxQ3UzM05mYkNOTzJMRFNEY0xYRTcwZnN2UmlBSzJ5Y3dsVlBmN2wtZUhFQ0NYMXFOcHExc2JCMGZlTGpyMU9iVFk4R2w4WFcydUpteW5EbGMyVTJtTHBCT1FuQ2JtSVpDVVFVWkF5eFFYTnZRc3V3?oc=5","date":"2024-04-30","type":"deal","source":"The Pharma Letter","summary":"Harmony Biosciences acquires Epygenix - The Pharma Letter","headline":"Harmony Biosciences acquires Epygenix","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxOUGJSeVhzYkYydWFEdm5wRER5alJJN2pPYktpbkh4Y1I5eE93TkhTc3BUTFdoRWpSOE12VHdHZTZYVXN5bm0zWmxzemJiUWlyN1N1dW9kRDZfYmYzenJPZW5wb0cxWDhaUW5RYWZHUVB1X1VGbVhYb0hQTlNKdUtBcjlzSEZrZWd0RTBqNkhiQjFLemFMRmpIUmZnZUJ4WXZlaDlHZHF4d2UyNXhEU3ZldnhNbUJMamVjSnhPbjBvSkhTeFhwMzRjbUJpclJZTTk3YzhFaC1sczJZaWdtTWFyZ3FUd1EtU0hRc0tMWmpsOFFmM3kxODMwZUZOR0VMZHFLMjk3bEp2YnV1UXl0OHF1eEd4LWRrN1pMUTlXcQ?oc=5","date":"2024-04-30","type":"deal","source":"PR Newswire","summary":"Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets - PR Newswire","headline":"Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOeWRoUDgzR2hVSWIybEtLMjZJTENEZENNNjNSZmoxdG9fN0IyTVlETGtnT1UteTNCdmRWRktEeUZ4SmNyUldsUDF2M00xZU9hV2RYb3o5NWxJWVBIZURiQkRvRHBxaXZLdHpLWWtZSXFuNFlOSDZmdHJNYWZjc2xEd0RhTFlGTzZ5UkdWd2Y4VFI4d2FGemctOURTUDcwanRPOEx6Q3E4czZra3kwWU5mMEpGRQ?oc=5","date":"2024-04-30","type":"deal","source":"Fierce Biotech","summary":"Sweet Harmony: Neuro biotech buys Epygenix and its epilepsy meds for $35M upfront - Fierce Biotech","headline":"Sweet Harmony: Neuro biotech buys Epygenix and its epilepsy meds for $35M upfront","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNFZPWlBnNUdXYkFvREtESDJJVWNMenZHMUN4eUd4ME9MNjB0S0ZtS2VEZFZXcFNXX3ppVUFkM1dCNGdoWmZnNGo1RVR3ZzJIc3FrSC1qQjh0Vk1ua3RPSWVuQ2x3REZLT3h1ZS1OY3BZU0lRTUlSalltMXp6dktLSURjTUtWaGI4d1o1Uk5Ud3MtRUg1TGl1S3FzT21CQld0TldsM2xsWUg?oc=5","date":"2022-03-15","type":"pipeline","source":"newswire.com","summary":"Epygenix Therapeutics Announces Appointment of Darren Cline as CEO - newswire.com","headline":"Epygenix Therapeutics Announces Appointment of Darren Cline as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPTUgtUnc2Z0haM182SzRXVDllOXhiOXMyX01xYXZlY0Z5ckE3OEE2U3FHWlNYNWhLT1BPdmg3NmxOblptckFhMVhET2F2VXJoTGtEUnJ4QXZ6TWlNbEVUd0J4WjYyNldfb3RicXJGWlllZXV1OEJieDY4ZDRTYnRPM19IcUZ5LW1ITXpxWHU5amZqdjRHMElSZ1hDSndTVmhW?oc=5","date":"2021-05-03","type":"pipeline","source":"Fierce Pharma","summary":"Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies - Fierce Pharma","headline":"Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}